Pharma BD Deal Intelligence
First-in-class approval delivered, but launch badly missed guidance and a 2024 boxed warning plus new Bayer rival now cloud the payback math
Full analysis, sources & comparables →Framed the up-to-$850M acquisition as Astellas extending its women's health footprint beyond Mirabegron, with fezolinetant offering a differentiated…
Called the Ogeda exit one of the largest European biotech M&A deals of 2017 and a validation of Belgium's biotech ecosystem.
Reported positive Phase 3 SKYLIGHT trial readouts, framing fezolinetant's path to FDA filing as a head-to-head race with Bayer's elinzanetant for the…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Astellas agreed to acquire Ogeda for up to EUR 800M (~$850M), with EUR 500M (~$531M) upfront for 100% of equity and up to EUR 300M (~$319M) in clinical/regulatory milestones for fezolinetant. Fezolinetant is a selective NK3 receptor antagonist with positive Phase 2a data in menopause-related vasomotor symptoms.
First-in-class approval delivered, but launch badly missed guidance and a 2024 boxed warning plus new Bayer rival now cloud the payback math
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Astellas Pharma Inc. / Ogeda SA (this deal) | 2017 | $850M | 59 |
| Astellas Pharma Inc. / Seagen Inc. | 2009 | $4.5B | 95 |
| Astellas Pharma Inc. / Ganymed Pharmaceuticals | 2016 | $1.4B | 81 |
| Astellas Pharma Inc. / Sangamo Therapeutics, Inc. | 2026 | $50M | 63 |
| Astellas Pharma Inc. / Ocata Therapeutics, Inc. | 2015 | $379M | 41 |
| Astellas Pharma Inc. / Optimer Pharmaceuticals, Inc. | 2012 | $90M | 38 |
| Astellas Pharma Inc. / OSI Pharmaceuticals | 2010 | $4.0B | 33 |
← Browse all deals · How we score deals
More: 2017 deals · Astellas Pharma Inc. deals · Women's Health deals